Live Breaking News & Updates on Sumitomo Dainippon Pharma Oncology|Page 5

Stay updated with breaking news from Sumitomo dainippon pharma oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pancreatic Cancer Pipeline Review | A Drug Pipeline

Pancreatic Cancer Pipeline is enriched with novel therapeutic strategies, including a broad range of therapies targeting diverse biologic processes. The. ....

United States , Takara Bio , Erytech Pharma , Sumitomo Dainippon Pharma , Los Angeles , Acerta Pharma , Bristol Myers Squibb , Asclepius Technology Company Group , Rafael Pharmaceuticals , Silenseed Ltd , Rgene Corporation , Ability Pharmaceuticals , Panbela Therapeutics Inc , Galera Therapeutics Inc , Rexahn Pharmaceuticals Inc , Jiangsu Hengrui Medicine Co , Wuhan Binhui Biotechnology Co Ltd , Carsgen Therapeutics Ltd , Drug Administration , Pancreatic Cancer Key Companies , Sd Pharma , Celldex Therapeutics Inc , Ascentage Pharma Group Inc , Biopharmaceuticals Inc , Golden Biotechnology Corporation , Everfront Biotech Co Ltd ,

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

/PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today. ....

United States , United Kingdom , Sumitomo Dainippon Pharma , Patricias Andrews , Sumitomo Dainippon Pharma Oncology Inc , World Health Organization , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd , Dainippon Pharmaceutical Co Ltd , Sumitomo Dainippon Pharma Oncology , Chief Executive Officer , Global Head , Dainippon Pharma Oncology , Dainippon Pharma , Private Securities Litigation Reform Act , Sterol Metabolites Regulate Growth , Dependent Tumors , Key Characteristic , Breast Cancer Stem Cells Influencing Patient ,

Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021

Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.
The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator TP-1454, PIM inhibitor TP-3654, TNK1 inhibitor TP-5809 and CDK9 inhibitor alvocidib. Additionally, Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sumitomo Dainippon Pharma Oncology (SDP Oncology), presented findings fro ....

United Kingdom , United States , Sumitomo Dainippon Pharma , Patricias Andrews , American Association For Cancer Research , Sumitomo Dainippon Pharma Oncology Inc , European Union , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd , Dainippon Pharmaceutical Co Ltd , Sumitomo Dainippon Pharma Oncology , American Association , Cancer Research , Annual Meeting , Global Head , Dainippon Pharma Oncology , Dainippon Pharma , Private Securities Litigation Reform Act , Potential Target , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , பற்ரிசியச் ஆண்ட்ரூஸ் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , ஐரோப்பிய தொழிற்சங்கம் , ஸூமிடோமொ மருந்துகள் இணை லிமிடெட் , அமெரிக்கன் சங்கம் ,

Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study of Napabucasin Fails to Reach Primary Endpoints in Patients with Previously Treated Metastatic Colorectal Cancer

Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study of Napabucasin Fails to Reach Primary Endpoints in Patients with Previously Treated Metastatic Colorectal Cancer
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 9, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS). Napabucasin in combination with FOLFIRI failed to show significant OS improvement in the general study population and in patients whose tumor was positive for the phosphorylated signal transducer and activator of transcription 3 (pSTAT3) biomarker. ....

United Kingdom , United States , Sumitomo Dainippon Pharma , Patricias Andrews , Sumitomo Dainippon Pharma Oncology Inc , European Union , Cancer Treatment Centers Of America , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd , American Cancer Society , Dainippon Pharmaceutical Co Ltd , Sumitomo Dainippon Pharma Oncology , Global Head , Dainippon Pharma Oncology , Dainippon Pharma , Private Securities Litigation Reform Act , Cancer Facts , Treatment Centers , Metastatic Colorectal Cancer , Updated September , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , பற்ரிசியச் ஆண்ட்ரூஸ் , ஐரோப்பிய தொழிற்சங்கம் , புற்றுநோய் சிகிச்சை மையங்கள் ஆஃப் அமெரிக்கா , ஸூமிடோமொ மருந்துகள் இணை லிமிடெட் ,

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes

Share this article
Share this article
CAMBRIDGE, Mass., Jan. 19, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).
The management of anemia in patients with MDS is challenging as this patient population tends to be older and often have non-hematological comorbidities which can make them relatively intolerant to therapy, said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Dainippon Pharma Oncology (SDP Oncology). Given the high unmet medical need, we are looking forward to learning more about the potential of TP-0184 in this patient population. ....

United States , United Kingdom , Sumitomo Dainippon Pharma , Patricias Andrews , Sumitomo Dainippon Pharma Oncology Inc , European Union , Sumitomo Dainippon Pharma Co Ltd , Prnewswire Sumitomo Dainippon Pharma Oncology Inc , Sumitomo Pharmaceuticals Co Ltd , Dainippon Pharmaceutical Co Ltd , Dainippon Pharma Oncology , Chief Executive Officer , Global Head , Sumitomo Dainippon Pharma Oncology , Dainippon Pharma , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பற்ரிசியச் ஆண்ட்ரூஸ் , ஐரோப்பிய தொழிற்சங்கம் , ஸூமிடோமொ மருந்துகள் இணை லிமிடெட் , தலைமை நிர்வாகி அதிகாரி , உலகளாவிய தலை , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,